Cohance Life

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE03QK01018
NSEID: COHANCE
BSEID: 543064
View on NSE | View on BSE

INR

303.40

-4.15 (-1.35%)

BSENSE

Apr 06

BSE+NSE Vol: 15.64 lacs

{
  "main_header": {
    "sid": 1003386,
    "name": "Cohance Life",
    "stock_name": "Cohance Life",
    "full_name": "Cohance Lifesciences Ltd",
    "name_url": "stocks-analysis/cohance-life",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "303.40",
    "chg": -4.15,
    "chgp": "-1.35%",
    "dir": -1,
    "prev_price": "307.55",
    "mcapval": "11,607.09 Cr",
    "mcap": "Small Cap",
    "scripcode": 543064,
    "symbol": "COHANCE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE03QK01018",
    "curr_date": "Apr 06",
    "curr_time": "",
    "bse_nse_vol": "15.64 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 06, 2026",
    "traded_date_str": "2026 04 06",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cohance-life-1003386-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cohance Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-sell-3927184",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_mojoScore_3927184.png",
        "date": "2026-03-31 10:10:37",
        "description": "Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-3923388",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_valuationdot_3923388.png",
        "date": "2026-03-30 08:01:55",
        "description": "Cohance Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing headwinds in the Pharmaceuticals & Biotechnology sector. This change, driven primarily by adjustments in its price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Amidst Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-amidst-sector-challenges-3909116",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_valuationdot_3909116.png",
        "date": "2026-03-24 08:02:07",
        "description": "Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid challenging sector dynamics and a significant divergence from peer valuations. Despite a modest day gain of 0.58%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered outlook for investors."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-sell-3902695",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_mojoScore_3902695.png",
        "date": "2026-03-20 10:10:45",
        "description": "Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Cohance Lifesciences Ltd Valuation Shifts Amidst Challenging Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-valuation-shifts-amidst-challenging-market-performance-3897962",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_valuationdot_3897962.png",
        "date": "2026-03-18 08:01:13",
        "description": "Cohance Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of early 2026. Despite a modest day gain of 2.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market enthusiasm compared to its historical highs and peer benchmarks within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Cohance Lifesciences Ltd Stock Falls to 52-Week Low of Rs.267.85",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-stock-falls-to-52-week-low-of-rs26785-3880281",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_priceRelatedfactors_3880281.png",
        "date": "2026-03-09 13:51:15",
        "description": "Cohance Lifesciences Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.267.85 today, marking a significant decline amid broader market pressures and company-specific performance issues."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-sell-3878616",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_mojoScore_3878616.png",
        "date": "2026-03-09 10:10:56",
        "description": "Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-sell-3878614",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CohanceLifescie_mojoScore_3878614.png",
        "date": "2026-03-08 10:10:38",
        "description": "Cohance Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Cohance Lifesciences Declines 9.39%: 5 Key Factors Behind the 52-Week Lows",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-declines-939-5-key-factors-behind-the-52-week-lows-3878153",
        "imagepath": "",
        "date": "2026-03-07 12:06:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Mar:</strong> New 52-week low at Rs.298</p>\n                    <p><strong>4 Mar:</strong> Further 52-week low at Rs.296.5</p>\n                    <p><strong>5 Mar:</strong> Continued decline to Rs.289.35 with valuation upgrade</p>\n                    <p><strong>6 Mar:</strong> Week closes at fresh 52-week low Rs.281.25</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.303.70</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.279.75</div><div class=\"stat-change negative\">-9.39%</div><..."
      }
    ],
    "total": 532,
    "sid": "1003386",
    "stock_news_url": "https://www.marketsmojo.com/news/cohance-lifesciences-1003386"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "02-Apr-2026",
      "details": "Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Appointment of Company Secretary and Compliance Officer",
      "datetime": "30-Mar-2026",
      "details": "Appointment of Mr. Sisir K. Mishra as Company Secretary and Compliance Officer of the Company",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Mar-2026",
      "details": "Closure of Trading Window",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has declared <strong>100%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 25 Sep 20",
          "dt": "2020-09-25",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cohance Lifesciences Ltd is Rated Sell

2026-03-31 10:10:37

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Cohance Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-03-30 08:01:55

Cohance Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing headwinds in the Pharmaceuticals & Biotechnology sector. This change, driven primarily by adjustments in its price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

Read full news article

Cohance Lifesciences Ltd Valuation Shifts Amidst Sector Challenges

2026-03-24 08:02:07

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid challenging sector dynamics and a significant divergence from peer valuations. Despite a modest day gain of 0.58%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a more tempered outlook for investors.

Read full news article

Cohance Lifesciences Ltd is Rated Sell

2026-03-20 10:10:45

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Cohance Lifesciences Ltd Valuation Shifts Amidst Challenging Market Performance

2026-03-18 08:01:13

Cohance Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of early 2026. Despite a modest day gain of 2.63%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now reflect a more tempered market enthusiasm compared to its historical highs and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Read full news article

Cohance Lifesciences Ltd Stock Falls to 52-Week Low of Rs.267.85

2026-03-09 13:51:15

Cohance Lifesciences Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.267.85 today, marking a significant decline amid broader market pressures and company-specific performance issues.

Read full news article

Cohance Lifesciences Ltd is Rated Sell

2026-03-09 10:10:56

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Cohance Lifesciences Ltd is Rated Sell

2026-03-08 10:10:38

Cohance Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.